Opko Health Sells Diagnostics Business to LabCorp
Company Announcements

Opko Health Sells Diagnostics Business to LabCorp

Opko Health Inc (OPK) just unveiled an update.

OPKO Health and its subsidiary BioReference have agreed to sell their clinical diagnostics and reproductive health lab testing business, excluding operations in New York and New Jersey, to LabCorp for approximately $237.5 million. This major transaction will see certain assets, liabilities, and employees transfer to the buyer, with standard legal provisions and conditions in place. The deal is subject to customary closing conditions and regulatory approvals, and does not hinge on financing. It also includes provisions against OPKO engaging in alternative transaction discussions, and a potential termination fee for regulatory clearance failures.

See more data about OPK stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskOPKO Health Shows Strategic Progress in Q3 2024
TheFlyOpko Health reports Q3 EPS 3c, consensus (9c)
TheFlyAspira Women’s Health expands collaboration with Bioreference
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App